- Ann.Oncol. 18(10):1745-1747 (2007)
- Lancet 370(9604):2011-2019 (2007)
- Clin.Res.Cardiol. 96(11):829-830 (2007)
- Nat.Rev.Cancer 7(5):332-344 (2007)
- Nat.Rev.Drug Discov. 6(9):734-745 (2007)
- Eur.J.Cancer 42(18):3127-3139 (2006)
- Nat.Rev.Cancer 7(6):475-485 (2007)
- N.Engl.J.Med. 358(1):95-97 (2008)
- J Clin Oncol 26(11):1810-1816 (2008)
- J.Clin.Oncol. 27(25):4169-4176 (2009)
- Cancer Chemother.Pharmacol. (2009)
- J.Clin.Oncol. 26(32):5204-5212 (2008)
- The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathwayCurr.Clin.Pharmacol. 3(2):132-143 (2008)
- Clin.Cancer Res. 3(12 Pt 1):2187-2190 (1997)
- Blood 103(9):3603-3605 (2004)


user